Tenon Medical (TNON) Q3 2026 earnings review
Tenon Medical clears its debt, but share count jumps eightfold
Tenon Medical paid off its debt and returned to quarterly sales growth, but existing shareholders paid for the rescue through heavy dilution. Revenue rose 22% from a year ago to $1.4 million, and gross margin recovered to 66% after regulators cleared reusable surgical tools. Chief executive Steven M. Foster raised $15.6 million to clear all convertible notes and end September with $8.3 million in cash.
| Revenue | $1.4M +22% from a year ago, +12% from last quarter |
|---|---|
| Gross margin | 66.3% +2.7 percentage points from last quarter |
| Operating loss | $3.1M improved from $3.4M a year ago |
| Ending common shares | 2.68M up from 0.33M three months ago |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because solving the September debt deadline multiplied the common share count more than eightfold in three months while cash burn stays high. Paying off the notes and meeting Nasdaq equity rules removed the immediate default threat, and the 12% sales rebound from last quarter broke a two-quarter slide. The bad news: at a $3.1 million quarterly operating loss, $8.3 million in cash covers less than three quarters by our math.
The question now is whether new surgical tools and a new sales chief can lift revenue fast enough to shrink the cash burn before Tenon needs another stock offering. Either surgeon training converts into steady hospital orders across both implant systems, or expanding the direct sales force lifts payroll faster than procedures. Fourth-quarter revenue against last winter's $1.5 million peak will tell.
🐂 Bull Case
Debt Paid Off and Nasdaq Rules Met
Tenon Medical entered the third quarter facing two immediate survival threats. The spine-implant maker owed about $5.16 million on senior convertible notes maturing on September 11, and its stockholders' equity had fallen into a $1.7 million deficit, violating Nasdaq listing rules.
Management raised about $15.6 million in gross proceeds during the quarter through five separate stock and warrant transactions. The company used part of that cash to pay off the convertible notes ahead of schedule, leaving zero debt on the balance sheet. Stockholders' equity rose to $9.2 million, and a 1-for-35 reverse stock split in August brought the share price back above Nasdaq's minimum threshold.
Clearing the debt and keeping the stock listing removes the immediate default risk that hung over the business in the first half of the year. What to watch: net cash used in operating activities once Tenon files its full quarterly report. That figure will show how much of the $15.6 million raise went to banking fees and working capital rather than the bank account.
Sales Grew Again From Last Quarter
Tenon sells surgical implants to fuse the sacroiliac joint, which connects the lower spine to the pelvis. Quarterly sales had slipped for two quarters in a row after peaking at $1.5 million in the fourth quarter of 2025, raising the risk that surgeon training sessions were not turning into hospital procedures.
Revenue rebounded 12.0% from the second quarter to $1.43 million, halting the sequential slide. Compared with a year ago, sales rose 22.1%, stepping down from 126.8% growth in the second quarter because Tenon bought its SImmetry+ lateral fusion system in August 2025, so the year-ago comparison now includes two months of that acquired product.
One rebound quarter eases the concern over falling sales, though revenue remains below last winter's peak. What to watch: fourth-quarter revenue against the $1.5 million peak from the fourth quarter of 2025, the first full-quarter comparison that includes SImmetry+ in both periods. A reading above $1.5 million would show true underlying growth across the combined product line.
Reusable Tools Lifted the Gross Margin
In July, the Food and Drug Administration cleared an update to Catamaran, Tenon's implant system inserted from the back of the pelvis, that "reclassifies certain instruments to reusable status". Management had said this change would lower the cost of each surgery starting in the third quarter, after gross margin dipped to 63.6% in the second quarter.
Gross margin recovered by 2.7 percentage points from last quarter to 66.3%, and edged up 0.4 percentage points from a year ago. Higher surgical volume helped spread fixed factory overhead, while reusable Catamaran tools cut per-case supply costs. Total operating expenses also fell 3.1% from a year ago to $4.04 million, as general and administrative overhead dropped by 81.5 percentage points of revenue on lower legal and professional fees.
What to watch: fourth-quarter gross margin as the new lateral screw scales up. Holding above 66% would confirm that reusable instruments permanently lowered manufacturing costs.
Two New Spine Tools Advance
Since buying SImmetry+, which approaches the joint from the side, Tenon has worked to upgrade the system's implants and surgical tools to win over spine surgeons. During the third quarter, the medical device group began the full commercial rollout of its 3D-printed lateral screw, after initial test surgeries brought in about $1.2 million in revenue over the prior ten months.
In late October, surgeons also completed the first clinical cases using the Quickstep Decorticator, a tool built to "streamline joint decortication and simplify the SImmetry+ surgical workflow" by preparing the bone surface for fusion. Tenon also added eight US patents so far in 2026, bringing its US total to 38.
What to watch: the full commercial launch of the Quickstep Decorticator, which management targets for the first quarter of 2027. An on-time launch would complete the upgraded SImmetry+ toolkit for the new sales leadership to sell.
🐻 Bear Case
Paying Off Debt Multiplied Shares by Eight
Because Tenon burns cash every quarter, it relies on issuing stock and warrants to pay its bills and clear its debt. To raise $15.6 million in gross proceeds during the third quarter, the company tapped five separate financing sources, and existing shareholders paid a steep price in ownership.
- Ending common shares: 2,682,721 at September 30, up 711.3% from 330,670 at June 30 by our math
- Third-quarter fundraising: $4.2 million public offering, $3.0 million private placement, $2.9 million warrant inducement, $2.8 million at-the-market sales, and $2.7 million warrant exercises
- Warrant inducement charge: $3.1 million in non-cash expense to persuade holders to exercise warrants
- Reported net loss: doubled to $6.64 million from $3.34 million a year ago
By our math, stripping out the $3.1 million warrant charge and $0.7 million of non-cash note interest leaves a clean net loss of $2.84 million. Even so, multiplying the share count more than eightfold in ninety days means each share now owns a fraction of the business it held in June. What to watch: remaining unexercised warrants in the upcoming quarterly filing, which will show how much dilution overhang still sits above the common stock.
Eight Million Cash Covers Under Three Quarters
"With our convertible notes now behind us, our attention is fully on growth," chief executive Steven M. Foster said. Foster pointed to the $8.27 million cash balance at the end of September, up from $1.68 million in June, as proof of a strengthened balance sheet.
The numbers show that financing remains a pressing issue. Tenon lost $3.09 million from operations in the third quarter alone. By our math, starting with $1.68 million in June and adding $15.6 million in gross proceeds should have yielded $17.28 million, meaning about $9.01 million went out the door for the $5.16 million note payoff, operating burn, and financing fees.
At the third-quarter operating loss rate of $3.09 million, $8.27 million of cash covers 2.7 quarters by our math, and the press release safe harbor still notes substantial doubt about Tenon's ability to continue as a going concern. Hiring direct sales reps will add payroll before new reps generate surgery revenue. What to watch: fourth-quarter operating loss and ending cash, which will show whether new sales hires speed up the cash burn.
Risks This Quarter Didn't Answer
Three standing questions about commercial execution and the product pipeline got no new numbers in the third-quarter release.
- Surgeon training count: missing for a second straight quarter after management replaced per-quarter physician counts with a half-year event growth percentage in the second quarter; the earnings call may provide a number.
- Surgical case volumes by platform: undisclosed, making it impossible to separate underlying Catamaran growth from acquired SImmetry+ procedures; the quarterly filing or call may break them out.
- Third surgical approach: no update on the posterior SI-joint system previously slated for initial clinical cases in the fourth quarter of 2026; fourth-quarter announcements will show if the timeline slipped.
👓 Other Themes
New Sales Chief Steps In
Tenon hired Thomas Batton Jr. as Chief Revenue Officer starting October 1 to lead its sales team. Batton brings over 15 years of medical device sales leadership across spine and SI-joint fixation. The company plans to hire more direct sales representatives and add distributor partners under his leadership, a push that will test management's pledge of "maintaining discipline on spend" while operating losses run above $3 million a quarter.
💲 Other KPIs
Weighted-average shares used to calculate per-share loss jumped 275.3% from last quarter and 421.6% from a year ago, to 1.23 million. Because Tenon issued shares throughout the third quarter, the average count lags the quarter-end total of 2.68 million shares, which lifted reported per-share loss improvements.
Uncollected customer bills fell 12.6% from $1.95 million at the end of June to $1.70 million, even as quarterly revenue grew 12.0% over the same period. Collecting older bills faster than new sales were booked helped bring cash in during the quarter, leaving receivables unchanged from December's $1.70 million.
Implant and instrument stock on hand rose 12.6% from $783 thousand in June after shrinking in both the first and second quarters. The medical device maker built inventory to support the full commercial launch of its 3D-printed lateral screw, though stock remains 16.3% below December's $1.05 million level.
❓ Key Questions
How did sales split between Catamaran and SImmetry+?
The third quarter is the first period where the year-ago comparison includes two months of acquired SImmetry+ revenue. Without procedure counts or revenue by platform, investors cannot tell whether original Catamaran sales are growing or shrinking.
How many surgeons completed training in the third quarter?
Management previously called surgeon training its leading indicator, but stopped giving quarterly physician counts after the first quarter of 2026. The third-quarter release gave neither a headcount nor an event growth rate.
How many warrants remain outstanding after the September inducement?
Tenon issued common shares and induced warrant exercises to raise $15.6 million, expanding its share count more than eightfold in one quarter. Investors need the remaining warrant count and strike prices to measure future dilution.
How much will hiring direct sales reps add to quarterly expenses?
With a new Chief Revenue Officer onboard in October, Tenon plans to hire direct sales representatives while promising spend discipline. Direct reps add fixed salary cost before they win hospital committee approvals.